title: Humulone suppresses replication of respiratory syncytial virus and release of IL-8 and RANTES in normal human nasal epithelial cells.
abstract: Respiratory syncytial virus (RSV) is the major infectious agent causing serious respiratory tract inflammation in infants and young children. However, an effective vaccine and anti-viral therapy for RSV infection have not yet been developed. Hop-derived bitter acids have potent pharmacological effects on inflammation. Therefore, we investigated the effects of humulone, which is the main constituent of hop bitter acids, on the replication of RSV and release of the proinflammatory cytokine IL-8 and chemokine RANTES in RSV-infected human nasal epithelial cells (HNECs). We found that humulone prevented the expression of RSV/G-protein, formation of virus filaments and release of IL-8 and RANTES in a dose-dependent manner in RSV-infected HNECs. These findings suggest that humulone has protective effects against the replication of RSV, the virus assembly and the inflammatory responses in HNECs and that it is a useful biological product for the prevention and therapy for RSV infection.
authors: Frontier Laboratories of Value Creation, Sapporo Breweries Ltd, Shizuoka, 425-0013, Japan.
authors: Jun
authors: J
authors: Fuchimoto
authors: Takashi
authors: T
authors: Kojima
authors: Tamaki
authors: T
authors: Okabayashi
authors: Tomoyuki
authors: T
authors: Masaki
authors: Noriko
authors: N
authors: Ogasawara
authors: Kazufumi
authors: K
authors: Obata
authors: Kazuaki
authors: K
authors: Nomura
authors: Satoshi
authors: S
authors: Hirakawa
authors: Naoyuki
authors: N
authors: Kobayashi
authors: Tatsuro
authors: T
authors: Shigyo
authors: Shin-ichi
authors: S
authors: Yokota
authors: Nobuhiro
authors: N
authors: Fujii
authors: Hiroyuki
authors: H
authors: Tsutsumi
authors: Tetsuo
authors: T
authors: Himi
authors: Norimasa
authors: N
authors: Sawada
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D002470:Cell Survival; D002478:Cells, Cultured; D018946:Chemokine CCL5 / Q000378:metabolism*; D053138:Cyclohexenes / Q000494:pharmacology*; D004847:Epithelial Cells / Q000276:immunology / Q000821:virology*; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism*; D009297:Nasal Mucosa / Q000276:immunology / Q000821:virology; D012136:Respiratory Syncytial Viruses / Q000187:drug effects / Q000502:physiology*; D013729:Terpenes / Q000494:pharmacology*; D014764:Viral Proteins / Q000235:genetics / Q000378:metabolism; D014771:Virion / Q000187:drug effects / Q000502:physiology; D019065:Virus Assembly / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; C483024:CCL5 protein, human; D018946:Chemokine CCL5; D053138:Cyclohexenes; D016209:Interleukin-8; D013729:Terpenes; D014764:Viral Proteins; C007966:humulon
references: Virology. 2006 Mar 15;346(2):427-39
references: 16330064
references: Mol Pharmacol. 2008 Aug;74(2):432-42
references: 18477669
references: Cell Tissue Res. 2007 Oct;330(1):63-74
references: 17701057
references: Pharmacol Res. 2010 Jun;61(6):489-98
references: 20227502
references: J Virol. 1998 Jul;72(7):5610-8
references: 9621019
references: Carcinogenesis. 2007 Jul;28(7):1491-8
references: 17372274
references: J Med Virol. 1989 Feb;27(2):124-30
references: 2466102
references: Toxicol Appl Pharmacol. 2011 Jan 1;250(1):29-38
references: 20932985
references: Virology. 2006 Jul 5;350(2):335-46
references: 16616290
references: Mol Biol Cell. 2011 Jul 1;22(13):2144-56
references: 21562222
references: Virology. 2007 Dec 20;369(2):309-23
references: 17825340
references: J Gen Virol. 1987 Sep;68 ( Pt 9):2521-4
references: 3655746
references: J Nat Prod. 2009 Jun;72(6):1220-30
references: 19476340
references: Cell Tissue Res. 2009 Nov;338(2):283-93
references: 19763625
references: J Gen Virol. 1991 Dec;72 ( Pt 12):3095-101
references: 1765771
references: Clin Vaccine Immunol. 2009 Jun;16(6):859-65
references: 19369476